- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Astellas Pharma Inc (ALPMY)
Astellas Pharma Inc stock price live, this page displays OTC ALPMY stock exchange data. View the ALPMY premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Astellas Pharma Inc real time stock price chart below.
What Is the Astellas Pharma Inc Stock Price Today?
The Astellas Pharma Inc stock price today is 16.46.
What Is the Stock Symbol for Astellas Pharma Inc?
The stock ticker symbol for Astellas Pharma Inc is ALPMY.
Is ALPMY the Same as $ALPMY?
$ALPMY is a common way to refer to the Astellas Pharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Astellas Pharma Inc Trade On?
Astellas Pharma Inc is listed and trades on the OTC Markets stock exchange.
Is Astellas Pharma Inc a Good Stock to Buy?
Determining whether Astellas Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Astellas Pharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALPMY quote. (ISIN: US04623U1025)
What Is the Astellas Pharma Inc Stock Price Today?
The Astellas Pharma Inc stock price today is 16.46.
What Is the Stock Symbol for Astellas Pharma Inc?
The stock ticker symbol for Astellas Pharma Inc is ALPMY.
Is ALPMY the Same as $ALPMY?
$ALPMY is a common way to refer to the Astellas Pharma Inc ticker symbol in social media, forums, and online discussions. The dollar sign is a shorthand convention used to indicate that it is a stock ticker symbol
What Stock Exchange Does Astellas Pharma Inc Trade On?
Astellas Pharma Inc is listed and trades on the OTC Markets stock exchange.
Is Astellas Pharma Inc a Good Stock to Buy?
Determining whether Astellas Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess the current Astellas Pharma Inc share price compared with the fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the ALPMY quote. (ISIN: US04623U1025)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.35
16.47
52 wk Range
8.91
17.35
Earnings results expected in 11 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
16.3516.47
52 wk Range
8.9117.35
Key Statistics
Edit
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Vol. (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ALPMY Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
19.00
Upside
+15.43%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Valuation implies a strong free cash flow yield
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to menopause; IZERVAY, a treatment for geographic atrophy secondary to age-related macular degeneration; EVRENZO, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It has a research collaboration with xFOREST Therapeutics to develop RNA-targeted therapies and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize an integrated diabetes self-management solution. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Compare ALPMY to Peers and Sector
Metrics to compare | ALPMY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipALPMYPeersSector | |
|---|---|---|---|---|
P/E Ratio | 14.5x | 19.4x | −0.5x | |
PEG Ratio | 0.02 | 0.05 | 0.00 | |
Price / Book | 2.6x | 1.7x | 2.6x | |
Price / LTM Sales | 2.3x | 2.3x | 3.2x | |
Upside (Analyst Target) | 18.6% | 9.5% | 47.6% | |
Fair Value Upside | Unlock | 7.8% | 6.1% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.00
(+15.43% Upside)
Earnings
Latest Release
Feb 04, 2026
EPS / Forecast
0.36 / 0.28
Revenue / Forecast
3.64B / 3.35B
People Also Watch
FAQ
What Is the Astellas Pharma Inc (ALPMY) Stock Price Today?
The Astellas Pharma Inc stock price today is 16.46 USD.
What Stock Exchange Does Astellas Pharma Inc Trade On?
Astellas Pharma Inc is listed and trades on the OTC Markets.
What Is the Stock Symbol for Astellas Pharma Inc?
The stock symbol for Astellas Pharma Inc is "ALPMY."
What Is the Astellas Pharma Inc Market Cap?
As of today, Astellas Pharma Inc market cap is 29.39B USD.
What Is Astellas Pharma Inc's Earnings Per Share (TTM)?
The Astellas Pharma Inc EPS (TTM) is 179.17.
When Is the Next Astellas Pharma Inc Earnings Date?
Astellas Pharma Inc will release its next earnings report on Apr 27, 2026.
From a Technical Analysis Perspective, Is ALPMY a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Astellas Pharma Inc Stock Split?
Astellas Pharma Inc has split 2 times.
How Many Employees Does Astellas Pharma Inc Have?
Astellas Pharma Inc has 13643 employees.
What is the current trading status of Astellas Pharma Inc (ALPMY)?
As of Apr 16, 2026, Astellas Pharma Inc (ALPMY) is trading at a price of 16.46 USD, with a previous close of 16.02 USD. The stock has fluctuated within a day range of 16.35 USD to 16.47 USD, while its 52-week range spans from 8.91 USD to 17.35 USD.
What Is Astellas Pharma Inc (ALPMY) Price Target According to Analysts?
The average 12-month price target for Astellas Pharma Inc is 19.00 USD, with a high estimate of 19 USD and a low estimate of 19 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +15.43% Upside potential.
What Is the ALPMY Premarket Price?
ALPMY's last pre-market stock price is 16.47 USD. The pre-market share volume is 810.00, and the stock has decreased by 0.45, or 2.81%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.